Cost-Effectiveness of Transcranial Magnetic Stimulation and Virtual Reality-Based Cognitive Remediation for Depressive Symptoms among Cancer Patients: Protocol for a Three-Arm Randomized Controlled Trial

This paper presents a research protocol of a randomized controlled trial aimed to evaluate the feasibility and the cost-effectiveness of non-pharmacological interventions for depressive symptoms, quality of life, depression-related conditions, and cognitive function among patients with cancer. Specifically, repetitive transcranial magnetic stimulation (rTMS) and virtual reality-based cognitive remediation (VR-COG) will be analyzed, alongside standard treatment as usual (TAU), in comparison to TAU alone.

100 participants will be enrolled: 60 from the Health Trust of Ferrara randomized 1:1:1 to (a) TAU, (b) rTMS + TAU, and (c) VR-COG + TAU, and 40 from the University Hospital of Cagliari randomized 1:1 to (a) TAU and (b) VR-COG + TAU. The inclusion criteria will be as follows: patients aged 18 years and older, both sexes, a diagnosis of oncological disease within the last 5 years in a non-advanced stage, a diagnosis of major depressive disorder according to DSM-5 criteria, and a score of≥14 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17). The VR-COG program will include a series of exercises in virtual sailing scenarios using the software CEREBRUM. The rTMS program will be delivered at 50% of the resting motor threshold. Personalized targets created for each individual will be located at various cortical depths. TAU will include psychiatric visits and psychological counseling. All the interventions will last 3 months, with pre-post evaluation for outcomes of interest and 3-6 months of follow-up. The study has been registered on the ClinicalTrials.gov website with ID no. NCT06589544.

The results of the trial will be published in international peer-reviewed journals and will be disseminated at international meetings and congresses.

The results of this study will be useful for obtaining knowledge for clinical practice regarding the feasibility and cost-effectiveness of innovative therapeutic approaches aimed at treating depression in individuals suffering from oncological pathologies.

The monitoring of the program's cost-effectiveness, encompassing both the screening and intervention phases, will enable policymakers to inform the implementation of this evidence in routine clinical practice.